Advertisement
COYA vs KNSA
Which Stock Would AI Choose? Coya Therapeutics (COYA) vs. Kiniksa Pharmaceuticals (KNSA) Stock Comparison
Key Takeaways
- COYA is a clinical-stage biotechnology company with no approved products, while KNSA is a profitable, commercial-stage biopharma with a blockbuster-track franchise.
- KNSA has demonstrated strong recent momentum, with revenue growth above 50% year over year and repeated upward revisions to its full-year outlook.
- COYA carries a "Strong Buy" analyst consensus and a wide gap between its current price and average price targets, reflecting high-risk, high-reward positioning.
- The two stocks sit at opposite ends of the risk spectrum, making this comparison relevant for both growth-oriented and catalyst-driven investors.
- For more detail on each name, explore COYA Major News, COYA Today's Price Move, KNSA Major News, and KNSA Today's Price Move.
- To see how automated strategies are positioning across these and other tickers, explore the Trending AI Robots.
Introduction
Investors evaluating biotech opportunities often face a choice between established commercial franchises and earlier-stage, catalyst-driven developers. This stock comparison places COYA and KNSA side by side to clarify how their relative performance and market positioning diverge in the current environment. COYA represents a speculative, pre-revenue wager on novel immunology science, while KNSA reflects a scaling, revenue-generating commercial story. Traders seeking momentum and fundamental stability, as well as long-term investors weighing risk against reward, may find the contrast instructive.
COYA Overview and Recent Performance
COYA, or Coya Therapeutics, Inc., is a Houston-based clinical-stage biotechnology company developing therapies that enhance the function of regulatory T cells (Tregs), immune cells that help control inflammation. Its lead candidate, COYA 302, is being studied in a Phase 2 trial for amyotrophic lateral sclerosis (ALS, a progressive neurodegenerative disease), with additional programs targeting frontotemporal dementia (FTD) and Alzheimer's disease.
In recent weeks, sentiment around COYA has been shaped by clinical progress and a licensing partnership with Dr. Reddy's Laboratories that validates the COYA 302 program and provides a path toward commercial scaling. The company has continued enrolling its ALSTARS trial across the U.S. and Canada, and it holds a modest cash position that management has extended through recent financing. The stock trades in the low single digits and has declined over the past year, yet analysts maintain a strong buy consensus with price targets well above the current share price, underscoring the wide gap between present fundamentals and anticipated catalysts.
KNSA Overview and Recent Performance
KNSA, or Kiniksa Pharmaceuticals International, plc, is a commercial-stage biopharmaceutical company focused on cardiovascular and inflammatory diseases. Its lead product, ARCALYST (rilonacept), is approved for recurrent pericarditis, a painful inflammation of the sac surrounding the heart, as well as certain rare inflammatory conditions, and is marketed through a collaboration with Regeneron.
Recent market activity has favored KNSA, driven by accelerating ARCALYST revenue growth of roughly 58% year over year and multiple upward revisions to its full-year guidance, now approaching blockbuster status. The company is profitable, holds a substantial cash balance with no debt, and is advancing next-generation pipeline candidates such as KPL-387 in a pivotal Phase 3 study. This combination of commercial momentum, improving profitability, and a funded pipeline has contributed to a pronounced 12-month share-price advance, although the resulting valuation multiple has drawn some caution among analysts.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from a much larger universe of hundreds of AI-powered trading bots that collectively monitor thousands of different tickers. Rather than listing every available bot, this section highlights only those strategies best aligned with prevailing market conditions, giving traders a focused view of what is currently working. The featured bots span diverse trading styles, timeframes, performance statistics, and sets of tickers, so no two operate identically. Exploring the Trending AI Robots page can help investors see how data-driven systems are interpreting names like COYA and KNSA alongside broader market signals.
Head-to-Head Comparison
The most fundamental contrast between these companies is stage. KNSA generates substantial, growing revenue and reported net income, whereas COYA remains pre-revenue, reliant on collaboration income and financing to fund development. Growth drivers differ accordingly: KNSA is driven by commercial execution, physician adoption, and market penetration, while COYA is driven by clinical trial readouts and regulatory milestones.
Risk profiles diverge sharply. COYA carries binary clinical and capital risk, but its depressed valuation leaves room for significant upside on positive data. KNSA faces execution and valuation risk after a strong run, but benefits from a robust balance sheet and recurring revenue. Sector exposure is similar in that both operate in the broader biotechnology space, yet their market positioning could hardly be more different in terms of momentum, stability, and downside protection.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor KNSA in the current environment. Its trend consistency, recurring revenue, profitability, and funded pipeline represent a more stable and verifiable setup than COYA, whose thesis hinges on future clinical catalysts. That said, COYA presents a higher-beta, event-driven opportunity that may appeal to catalyst-focused traders. The AI's preference should be read as a probabilistic assessment of relative positioning rather than a definitive prediction, and both names warrant monitoring as their respective data catalysts unfold.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is COYA is a Buy and KNSA is a Buy.
COYA's RSI Oscillator sits in oversold zone for 2 days
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where COYA advanced for three days, in 167 of 194 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
COYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on COYA as a result. In 65 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for COYA turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
COYA moved below its 50-day moving average on October 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for COYA crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
The 50-day moving average for COYA moved below the 200-day moving average on October 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where COYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for COYA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.686) is normal, around the industry mean (3.051). P/E Ratio (-2.907) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (11.062) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. COYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. COYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KNSA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for KNSA turned positive on October 27, 2026. Looking at past instances where KNSA's MACD turned positive, the stock continued to rise in 38 of 42 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on KNSA as a result. In 81 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
KNSA moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KNSA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where KNSA advanced for three days, in 231 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The 10-day RSI Indicator for KNSA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 34 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KNSA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
KNSA broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for KNSA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 1 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. KNSA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.127) is normal, around the industry mean (8.179). P/E Ratio (88.009) is within average values for comparable stocks, (-0.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.564) is also within normal values, averaging (181.047).
KNSA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 42 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 1 | |
SMR RATING 1..100 | 59 | |
PRICE GROWTH RATING 1..100 | 35 | |
P/E GROWTH RATING 1..100 | 40 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| COYA | KNSA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 71% |
| Momentum ODDS (%) | 3 days ago 84% | 1 day ago 85% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 80% |
| Advances ODDS (%) | 9 days ago 86% | 7 days ago 76% |
| Declines ODDS (%) | 1 day ago 86% | 3 days ago 74% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 67% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
COYA’s FA Score shows that 1 FA rating(s) are green while KNSA’s FA Score has 1 green FA rating(s).
- COYA’s FA Score: 1 green, 4 red.
- KNSA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
COYA’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 5 bullish TA indicator(s).
- COYA’s TA Score: 4 bullish, 7 bearish.
- KNSA’s TA Score: 5 bullish, 5 bearish.
Price Growth
COYA (@Biotechnology) experienced а -24.51% price change this week, while KNSA (@Pharmaceuticals: Generic) price change was +4.59% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.09%. For the same industry, the average monthly price growth was -12.05%, and the average quarterly price growth was -17.02%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -1.23%. For the same industry, the average monthly price growth was -7.21%, and the average quarterly price growth was +2.47%.
Reported Earning Dates
COYA is expected to report earnings on Nov 11, 2026.
KNSA is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (-2.09% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Generic (-1.23% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
COYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, COYA has been loosely correlated with EDIT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if COYA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To COYA | 1D Price Change % | ||
|---|---|---|---|---|
| COYA | 100% | -3.72% | ||
| EDIT - COYA | 50% Loosely correlated | +1.17% | ||
| VIR - COYA | 46% Loosely correlated | +2.00% | ||
| INMB - COYA | 44% Loosely correlated | -4.35% | ||
| KURA - COYA | 43% Loosely correlated | +0.92% | ||
| CADL - COYA | 42% Loosely correlated | +8.62% | ||
More | ||||
KNSA and
Correlation & Price change
A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with COYA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then COYA could also see price increases.
| Ticker / NAME | Correlation To KNSA | 1D Price Change % | ||
|---|---|---|---|---|
| KNSA | 100% | +2.74% | ||
| COYA - KNSA | 42% Loosely correlated | -3.72% | ||
| ABVC - KNSA | 40% Loosely correlated | +0.51% | ||
| JBIO - KNSA | 37% Loosely correlated | +4.59% | ||
| AMRN - KNSA | 36% Loosely correlated | -0.66% | ||
| SNDX - KNSA | 35% Loosely correlated | +9.08% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| URAA | 13.72 | 0.12 | +0.88% |
| DIREXION DAILY URANIUM INDUSTRY BULL 2X SHARES | |||
| PRMR | 28.20 | 0.05 | +0.17% |
| PeakShares RMR Prime Equity ETF (PRMR) | |||
| TNUK | 20.87 | N/A | N/A |
| Tortoise Nuclear Renaissance ETF | |||
| RLY | 36.75 | -0.19 | -0.51% |
| State Street Multi-Asset Real Return ETF (RLY) | |||
| ARDC | 11.55 | -0.13 | -1.11% |
| Ares Dynamic Credit Allocation Fund | |||